US9023368B2 - Colonic drug delivery formulation - Google Patents

Colonic drug delivery formulation Download PDF

Info

Publication number
US9023368B2
US9023368B2 US11/735,248 US73524807A US9023368B2 US 9023368 B2 US9023368 B2 US 9023368B2 US 73524807 A US73524807 A US 73524807A US 9023368 B2 US9023368 B2 US 9023368B2
Authority
US
United States
Prior art keywords
drug
formulation
coating
colon
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active, expires
Application number
US11/735,248
Other languages
English (en)
Other versions
US20070243253A1 (en
Inventor
Abdul Waseh Basit
Valentine Chidi Ibekwe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University College London
Original Assignee
University College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36571851&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US9023368(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University College London filed Critical University College London
Assigned to SCHOOL OF PHARMACY, UNIVERSITY OF LONDON reassignment SCHOOL OF PHARMACY, UNIVERSITY OF LONDON ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BASIT, ABDUL WASEH, IBEKWE, VALENTINE CHIDI
Publication of US20070243253A1 publication Critical patent/US20070243253A1/en
Assigned to UNIVERSITY COLLEGE LONDON reassignment UNIVERSITY COLLEGE LONDON ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON
Priority to US14/676,225 priority Critical patent/US9993435B2/en
Publication of US9023368B2 publication Critical patent/US9023368B2/en
Application granted granted Critical
Priority to US15/834,436 priority patent/US10369112B2/en
Priority to US16/354,683 priority patent/US10668023B2/en
Priority to US16/798,676 priority patent/US10758491B2/en
Priority to US15/929,260 priority patent/US10857103B2/en
Active legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/606—Salicylic acid; Derivatives thereof having amino groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Definitions

  • the present invention relates to a delayed release formulation with a core comprising a drug and a delayed release coating.
  • a delayed release formulation for a drug for delivering to the colon is a delayed release formulation for a drug for delivering to the colon.
  • the targeting of drugs to the colon can be utilised as a means of achieving local therapy or systemic treatment.
  • the colon is susceptible to a number of disease states, including inflammatory bowel disease, irritable bowel syndrome, constipation, diarrhoea, infection and carcinoma. In such conditions, drug targeting to the colon would maximise the therapeutic effectiveness of the treatment.
  • the colon can also be utilised as a portal for the entry of drugs into the systemic circulation.
  • Various formulations have been developed for colonic drug delivery, including pro-drugs as well as formulated dosage forms, with the latter being more popular since the concept once proved can be applied to other drugs.
  • WO-A-03/068196 discloses a specific delayed release coating for the bioactive prednisolone sodium metasulphobenzoate comprising glassy amylose, ethyl cellulose and dibutyl sebacate.
  • WO-A-01/76562 discloses peroral pharmaceutical formulation containing a drug and a chitosan (a polysaccharide obtained from chitin) for controlling its release.
  • the drug and the chitosan are mixed into a homogeneous mechanical powder mixture which granulated and then optionally tabletised.
  • the granulation may be performed with an enteric polymer (such as a coploymer of methacrylic acid) or the granules may be provided with a porous enteric coating.
  • WO-A-2004/052339 discloses a pH dependent drug release system which is a free-flowing powder of solid hydrophobic nano-spheres comprising a drug encapsulated in a pH-sensitive micro-sphere.
  • the nano-spheres are formed from the drug in combination with a wax material, and the pH-sensitive micro-sphere formed from a pH-sensitive polymer (such as a Eudragit® polymer) in combination with a water-sensitive material such as a polysaccharide.
  • a pH-sensitive polymer such as a Eudragit® polymer
  • Polysaccharides containing considerable amounts, preferably about 20 wt % to 100 wt %, of galactose and mannose units are particularly suitable with locust bean gum and guar gum being preferred.
  • Preferred film-forming polymers include acrylate polymers that are pH independent (insoluble throughout the GI tract) and pH dependent (insoluble in stomach juice but soluble in intestinal juice at pH 5.5 or above).
  • the reference exemplifies the use of a mixture of guar gum with either Eudragit RL 30 D (in a ratio of 41), Eudragit® L 30 D (in a ratio of 3:1) or Eudragit® S 100 (in a ratio of 2.5:1) as a tablet coating.
  • HylonTM VII an amylose-rich ( ⁇ 70 wt %) maize starch; National Starch, Germany
  • Dissolution of the tablets in acidic medium was rapid with more than 75% of the drug being dissolved within 15 minutes.
  • the coating did not contain a second film forming polymer.
  • a delayed release drug formulation comprising a particle with a core and a coating for the core, the core comprising a drug and the coating comprising a mixture of a first material which is susceptible to attack by colonic bacteria and a second material which has a solubility threshold at about pH 5 or above, wherein the first material comprises a polysaccharide selected from the group consisting of starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan.
  • the first material comprises a polysaccharide, preferably containing a plurality of glucose units.
  • the polysaccharide is starch, amylose or amylopectin, most preferably starch.
  • the person skilled in the art is capable of determining whether a material is susceptible to attack by colonic bacteria using techniques comprising part of the common general knowledge. For example, a pre-determined amount of a given material could be exposed to an assay containing an enzyme from a bacterium found in the colon and the change in weight of the material over time may be measured.
  • the polysaccharide preferably starch.
  • Starches are usually extracted from natural sources such as cereals; pulses; and tubers.
  • Suitable starches for use in the present invention are typically food grade starches and include rice starch; wheat starch; corn (or maize) starch; pea starch; potato starch; sweet potato starch; tapioca starch; sorghum starch; sago starch; and arrow root starch.
  • rice starch wheat starch; corn (or maize) starch
  • pea starch potato starch
  • sweet potato starch tapioca starch
  • sorghum starch tapioca starch
  • sago starch arrow root starch.
  • maize starch is exemplified below.
  • Starch is actually a mixture of two different polysaccharides, namely amylose and amylopectin. Different starches may have different proportions of these two polysaccharides. Most natural (unmodified) maize starches have from about 20 wt % to about 30 wt % amylose with the remainder being at least substantially made up of amylopectin. Starches suitable for use in the present invention typically have at least 0.1 wt %, e.g. at least 10% or 16%, preferably at least 35 wt %, amylose. “High amylose” starches, are starches having at least 50 wt % amylose. Particularly suitable starches have from about 65 wt % to about 75 wt %, e.g. about 70 wt % amylose.
  • Starches suitable for use in the present invention may have up to 100% amylopectin, more typically from about 0.1 wt % to about 99.9 wt % amylopectin.
  • Low amylose starches i.e. starches having no more than 50 wt % amylose and at least 50 wt % amylopectin, e.g. up to 75 wt % amylopectin and even as much as up to 99 wt % amylopectin, are suitable.
  • the starch may be, for instance, unmodified waxy corn starch.
  • “Low amylose” starch was not expected to be suitable, since low amylose starch is typically degraded by pancreatic enzymes in the small intestine.
  • Preferred starches have no more than 50 wt % amylopectin.
  • Particularly suitable starches have from about 25 wt % to about 35 wt % amylopectin, e.g. about 30 wt % amylopectin.
  • Preferred starches have amylose in its glassy form although amylose in its amorphous form may also be used in conjunction with the present invention.
  • Preferred starches are “off-the-shelf” starches, i.e. starches which require no processing prior to use in the context of the present invention.
  • Examples of particularly suitable “high amylose” starches include HylonTM VII (National Starch, Germany) or EurylonTM 7 (Roquette, Lestrem, France) or Amylogel 03003 (Cargill, Minneapolis, USA) all of which are examples of a maize starch having about 70 wt % amylose.
  • soluble we mean that 1 g of the second material requires less than 10,000 ml, preferably less than 5,000 ml, more preferably less than 1000 ml, even more preferably less than 100 ml or 10 ml of solvent to dissolve at a given pH.
  • Surrounding medium preferably means the medium in the gastro intestinal tract, such as the gastric juice or intestinal juice. Alternatively, the surrounding medium may be in the vitro equivalent of the medium in the gastrointestinal tract.
  • the normal pH of gastric juice is usually in the range of to 3.
  • the second material is insoluble below pH 5 and soluble at about pH 5 or above and soluble at about pH 5 or above and, thus, is usually insoluble in gastric juice.
  • Such a material may be referred to as an “enteric” material.
  • the pH threshold at which a material becomes soluble may be determined by a simple titration technique which would be part of the common general knowledge to the person skilled in the art.
  • the second material is typically a film-forming polymeric material such as an acrylate polymer, a cellulose polymer or a polyvinyl-based polymer.
  • suitable cellulose polymers include cellulose acetate phthalate (“CAP”); cellulose acetate trimellitate (“CAT”); and hydropropylmethylcellulose acetate succinate.
  • suitable polyvinyl-based polymers include polyvinyl acetate phthalate (“PVAP”).
  • the second material is preferably a co-polymer of a (meth)acrylic acid and a (meth)acrylic acid C 1-4 alkyl ester, for instance, a copolymer of methacrylic acid and methacrylic acid methyl ester.
  • a polymer is known as a poly(methacrylic acid/methyl methacrylate) co-polymer.
  • Suitable examples of such co-polymers are usually anionic and not sustained release polymethacrylates.
  • the ratio of carboxylic acid groups to methyl ester groups (the “acid:ester ratio”) in these co-polymers determines the pH at which the co-polymer is soluble.
  • the acid:ester ratio may be from about 2:1 to about 1:3, e.g. about 1:1 or, preferably, about 1:2.
  • the molecular weight (“MW”) of preferred anionic co-polymers is usually from about 120,000 to 150,000, preferably about 135,000.
  • the second material may be a copolymer of methacrylic acid and ethyl acrylate.
  • Eudragit® L100-55 poly(methacrylic acid/ethyl acrylate); acid:ester ratio of about 1:1; MW about 250,000; pH threshold of about 5.5 is suitable.
  • the Eudragit® co-polymers are manufactured and/or distributed by Degussa AG, Darmstadt, Germany.
  • film forming polymer materials may be used appropriate.
  • An example of a suitable mixture would include a mixture, e.g. a 1:1 mixture, of Eudragit® L and Eudragit® S.
  • a particular film forming polymer material e.g. a poly(methacrylic acid/methyl methacrylate) co-polymer, alone is preferred.
  • mixture of two suitable polymers at an appropriate ratio, applied as a film coating on to a core at least minimises, and can substantially eliminate, drug release in the stomach and small intestine.
  • Subsequent drug release in the colon is believed to occur by the combined active physiological triggers: i.e. by dissolution of the second material, particularly Eudragit® S, and digestion of the first material, e.g. starch or amylose.
  • the proportion of the first material to the second material is typically less than 99:1 and may in some circumstances be up to 50:50.
  • the proportion is usually up to 35:65 and is preferably from 15:85 to 35:65, e.g. 15:85 to 30:70.
  • the Inventor has discovered that a ratio of first material to second material from about 25:75 to about 35:65, e.g. about 30:70, is particularly suitable for targeting release of the drug to the colon, particularly if the first material is starch and the second material is Eudragit® S.
  • the mixture of first and second materials is preferably substantially homogenous.
  • excipients such as plasticisers for film formation (for example, triethyl citrate) and anti-tack agents (such as glyceryl monostearate) may be included in amounts up to 30% by weight of the final composition of the polymer coating preparation.
  • plasticisers for film formation for example, triethyl citrate
  • anti-tack agents such as glyceryl monostearate
  • the thickness of the coating of the particle is typically from about 10 ⁇ m to about 150 ⁇ m.
  • the thickness of a specific coating will, however, depend on the composition of the coating. For example, coating thickness is directly proportional to the amount of polysaccharide in the coating.
  • the coating thickness may be from about 70 ⁇ m to about 130 ⁇ m, and preferably from about 90 ⁇ m to about 110 ⁇ m.
  • the thickness (in ⁇ m) for a given coating composition is independent of core size.
  • the thickness of the coating may also be measured by the “theoretical weight gain” (“TWG”) of the coated formulation.
  • TWG for the present formulation will depend on a number of factors including the composition of the coating and the size of the core to be coated.
  • the TWG is typically from about 4% to about 12%, e.g. from about 5% to about 10%, preferably from about 8% to about 9%.
  • the TWG may be from about 15% to about 35%, e.g. from about 20% to about 30%, preferably about 25%.
  • the coating comprises a mixture of the first and second materials
  • the known multi-layer dosage form (disclosed for example in Milojevic et al. described above) in which an active core is coated first with an inner coating of amylose and then with an outer coating of Eudragit® L100.
  • such a multi-layer dosage form does not comprise a mixture of starch and Eudragit® L100.
  • the coating is preferably a single layer of a mixture of the first and second materials, preferably a homogenous mixture.
  • the formulation of the present invention may however have an additional layer either between the active core and the layer comprising the delayed release composition of the present invention and/or an outer layer coating the delayed release composition layer of the present invention.
  • the delayed release composition layer comprises a mixture of Eudragit® L and starch
  • the addition of an outer layer of a pH dependent release coating material having a pH threshold of about 7, e.g. Eudragit® S may be preferable.
  • the delayed release coating of the present invention is applied directly to the active core, i.e. there is no additional layer between this coating and the active core.
  • the delayed release coating of the present invention is preferably the outer coating of the formulation.
  • the composition preferably forms a coating around the bioactive which is most preferably mixture of starch and Eudragit® S.
  • the “bioactive” is usually the core comprising the drug.
  • the formulation comprises at least one particle with a core and a coating for the core.
  • the formulation may comprise any suitable coated oral dosage form including capsules; tablets; mini-tablets; pellets; granules; and crystals.
  • the minimum diameter of each particle is typically at least about 10 ⁇ 4 m, usually at least about 5 ⁇ 10 ⁇ 4 m and, preferably, at least about 10 ⁇ 3 m.
  • the maximum diameter is usually no more than 30 mm, typically no more than 20 mm and, preferably, no more than 10 mm.
  • the particle has a diameter from about 0.2 mm to about 15 mm, preferably from about 1 mm to about 4 mm (e.g. for pellets or mini-tablets) or from about 6 mm to about 12 mm (e.g. for certain tablets or capsules).
  • the term “diameter” refers to the largest linear dimension through the particle.
  • the formulation may comprise a plurality of particles in order to provide a single dose of the drug(s), particularly in embodiments in which the particle is “small”, e.g. having a diameter of less than 5 mm. Multi unit dosage forms comprising particles having a diameter of less than 3 mm are preferred.
  • the present invention has application in a multi-phasic drug release formulation comprising at least two pluralities of particles, e.g. coated pellets, in the same dosage form, e.g. a capsule, in which the particles of one plurality are differentiated from the particles of the or each other plurality by the coating.
  • the coatings may differ from one plurality to the next in terms of coating thickness or composition, e.g. the ratio and/or identity of components.
  • Multi-phasic drug release formulations would be particularly suitable for suffers of Crohn's disease affecting different regions along the intestine.
  • the “core” is usually a single solid body.
  • the core may consist of the drug(s) alone or may be a bead of edible material, e.g. sugar, which is coated with a layer comprising the drug(s). More usually, however, the core consists of a mixture of the drug(s) with a filler or diluent material, e.g. lactose or cellulose material such as microcrystalline cellulose; a binder, e.g. polyvinylpyrrolidone (“PVP”); a disintegrant, e.g. Ac-D-SolTM (i.e. croscarmellose sodium); and/or a lubricant, e.g magnesium stearate.
  • the core may be a compressed granulate comprising at least some of these materials.
  • Release from formulations according to the present invention is delayed until the intestine and preferably the colon. Release from certain formulations may also be sustained. However, in preferred formulations, release is pulsatile.
  • a formulation is usually defined as gastric resistant if there is less than 10 wt % drug release in acidic media after 2 hours.
  • Formulations according to the present invention typically display far less than 10 wt % drug release in acidic media and may be considered to be gastric resistant.
  • the formulations usually display less than 1 wt % drug release in acidic media and, typically, display substantially no drug release in acidic media.
  • starch is combined with an acrylate film forming material to form the coating for the core, typically less than 5% drug release occurs over 5 hours in conditions simulating the stomach and small intestine.
  • On combination of starch with a cellulosic film forming material for the coating for the core typically less than 10% drug release occurs over 5 hours in conditions simulating the stomach and small intestine.
  • the time between initial exposure to conditions suitable for drug release and the start of drug release is known as the “lag time”.
  • the “lag time” depends on a number of factors including coating thickness and composition.
  • Formulations according to the present invention usually display a lag time in colonic conditions of at least 30 minutes. In most embodiments of the present invention, the lag time is from about 30 minutes to about 3 hours and, in preferred formulations, the lag time is preferably from about 45 minutes to about 2 hours.
  • the time between initial exposure to conditions suitable for drug release and complete drug release also depends on a number of factors including coating composition and the nature of the drug. In most embodiments of the present invention, this time is usually no more than 5 hours. In preferred embodiments, this time is usually no more than 4 hours.
  • the time between initial release and complete release may be less than about 2 hours, preferably less than about 1.5 hours.
  • the core is a pellet having diameter of about 1 mm.
  • the core is a tablet having a diameter of about 8 mm.
  • the coating is preferably a 30:70 mixture of high amylose starch, e.g. EurylonTM 7, and an acrylic polymer, e.g. EudragitTM S.
  • the core is coated to a thickness of about 100 ⁇ m which is from about 8% to about 9% TWG for the tablet and from about 27% to about 32 wt % for the pellet.
  • a formulation according to the first aspect for use in a method of medical treatment of the human or animal body by therapy.
  • the core comprises at least one drug.
  • the formulation is usually used to administer a single drug as the sole therapeutically active component. However, more than one drug may be administered in a single formulation.
  • the formulation of the present invention is designed to administer a wide range of drugs. Suitable drugs include those drugs which are known for intestinal administration using known delayed release oral formulations.
  • the present invention may be used to administer drugs having a local or a systemic effect.
  • the formulation of the present invention has particular application in the intestinal administration of a drug comprising at least one acidic group such as a carboxylic acid group.
  • a drug comprising at least one acidic group such as a carboxylic acid group.
  • Such drugs may be acidic drugs or zwitterionic drugs.
  • An example of such a drug is 5-aminosalicylic acid (“5-ASA”).
  • the identity of the drug(s) in the formulation obviously depends on the condition to be treated.
  • the formulation has particular application in the treatment of IBD (including Crohn's disease and ulcerative colitis); IBS; constipation; diarrhoea; infection; and carcinoma, particularly colon or colorectal cancer).
  • the formulation may comprise at least one drug selected from the group consisting of anti-inflammatory agents (e.g. 5-ASA); steroids (e.g. prednisolone; budesonide or fluticasone); immunosuppressants (e.g. azathioprine; cyclosporin; and methotrexate); and antibiotics.
  • anti-inflammatory agents e.g. 5-ASA
  • steroids e.g. prednisolone; budesonide or fluticasone
  • immunosuppressants e.g. azathioprine; cyclosporin; and methotrexate
  • antibiotics e.g. 5-ASA
  • steroids e.g. prednisolone; budesonide or fluticasone
  • immunosuppressants e.g. azathioprine; cyclosporin; and methotrexate
  • the formulation may comprise at least one antineoplastic agent.
  • Suitable antineoplastic agents include fluorouracil; methotrexate; dactinomycin; bleomycin; etoposide; taxol; vincristine; doxorubicin; cisplatin; daunorubicin; VP-16; raltitrexed; oxaliplatin; and pharmacologically acceptable derivatives and salts thereof.
  • the formulation may comprise the anti-inflammatory agent, 5-ASA.
  • the formulation may comprise at least one active agent suitable for the treatment or prevention of these conditions.
  • Pharmacologically acceptable derivatives and/or salts of the drugs may also be used in the formulation.
  • An example of a suitable salt of prednisolone is methyl prednisolone sodium succinate.
  • a further example is fluticasone propionate.
  • the present invention has particular application in either the treatment of IBD (particularly, ulcerative colitis) or the prevention of colon cancer or colorectal cancer (primarily in colitis patients), both using 5-ASA. It also has application as a portal of entry of drugs into the systemic circulation via the colon. This is particularly advantageous for peptide and protein drugs which are unstable in the upper gastrointestinal tract.
  • the present invention may also be utilised for the purpose of chronotherapy.
  • a method of targeting a drug to the colon comprising administering to a patient a formulation as defined above.
  • a formulation as defined above in the manufacture of a medicament for the treatment or prevention of IBD (particularly ulcerative colitis); IBS; constipation; diarrhoea; infection; and cancer.
  • At least one drug selected from anti-inflammatory agents and steroids in the manufacture of a medicament comprising a formulation as defined above for use in the treatment of IBD.
  • at least one antineoplastic agent in the manufacture of a medicament comprising a formulation as defined above for use in the treatment of carcinoma.
  • 5-ASA in the manufacture of medicament comprising a formulation as defined above for use in the prevention of colon cancer or colorectal cancer.
  • a method of medical treatment or prevention of IBD or carcinoma comprises administering to a patient therapeutic amount of a formulation as defined above.
  • the formulation will typically comprise a therapeutically effective amount of the or each drug which may be from about 0.01 wt % to about 99 wt %, based on the total weight of the formulation.
  • the actual dosage would be determined by the skilled person using his common general knowledge.
  • “low” dose formulations typically comprise no more than about 20 wt % of the drug, and preferably comprise from about 1 wt % to about 10 wt %, e.g. about 5 wt %, of the drug.
  • “High” dose formulations typically comprise at least 40 wt % of the drug, and preferably from about 45 wt % to about 85 wt %, e.g. about 50 wt % or about 80 wt %.
  • a method of preparing a delayed release drug formulation according to the first aspect comprising:
  • a polymer coating preparation comprising a mixture of a first material which is susceptible to attack by colonic bacteria and a second material which has a pH threshold at about pH 5 or above,
  • the first material comprises a polysaccharide selected from the group consisting of starch; amylose; amylopectin; chitosan; chondroitin sulfate; cyclodextrin; dextran; pullulan; carrageenan; scleroglucan; chitin; curdulan and levan.
  • Preferred polysaccharides are as detailed above.
  • the core is preferably spray coated with said polymer coating preparation.
  • the method preferably comprises:
  • a fluidised bed spray coating machine is preferably used to coat the core(s) with the polymer coating preparation to form the particle(s) of the formulation.
  • the method comprises:
  • the first material is usually dispersed in at least one alcohol, preferably a C 1 to C 6 alcohol, e.g. methanol; ethanol; propan-1-ol; propan-2-ol; butan-1-ol; butan-2-ol; and mixtures thereof, particularly butan-1-ol alone, and then water is usually added subsequently with good agitation.
  • the resulting aqueous dispersion is usually heated to boiling and then cooled with stirring overnight.
  • the purpose of the alcohol(s) is to solvate the first material ready to form the aqueous dispersion.
  • the material can be dispersed directly in water.
  • the second material is typically dissolved in at least one solvent, for instance water or an organic solvent.
  • the organic solvent may be an alcohol, e.g. methanol; ethanol; propan-2-ol; methyl glycol; butyl glycol; acetone; methyl glycol acetate; and mixtures thereof such as acetone and isopropyl alcohol (e.g. in a ratio of about 4:6).
  • the second material is preferably dissolved in ethanol (preferably from 85 to 98%), under high speed stirring.
  • the polymer coating preparation is preferably formed by adding an appropriate quantity of the aqueous dispersion to the alcoholic solution, drop-wise under fast stirring.
  • the further excipient(s) such as a plasticiser (e.g. triethyl citrate) and/or a lubricant (e.g. glyceryl monostearate) is usually added to the preparation while stirring.
  • FIG. 1 is a graph depicting the dissolution profiles of mixed film coated prednisolone tablets at 5% TWG and Eudragit® S coated tablets at 5% TWG in pH 7.0 buffer;
  • FIG. 2 is a graph depicting the dissolution profiles mixed film coated tablets as for FIG. 1 but with 6% TWG;
  • FIG. 3 is a graph depicting the dissolution profiles of mixed film coated tablets as for FIG. 1 but with 7.4% TWG;
  • FIG. 4 is a graph depicting the dissolution profiles mixed film coated tablets as for FIG. 1 but with 8.3% TWG;
  • FIG. 5 is a graph depicting the dissolution profiles of prednisolone tablets coated with 30% starch:70% Eudragit S at various polymer weight gains and Eudragit® S coated tablets at 5% TWG;
  • FIG. 6 is a graph depicting the dissolution profile of prednisolone tablets coated with 30% starch:70% Eudragit® S in pH 6.8 buffer, with and without pancreatin;
  • FIG. 7 is a graph depicting drug release from prednisolone tablets coated to 8.3% TWG in pH 6.8 buffer containing 50 U/ml amylase;
  • FIG. 8 is a graph depicting the dissolution profile of 5-ASA tablets coated with 30% starch:70% Eudragit® S to 8.3% TWG in pH 6.8 buffer;
  • FIG. 9 is a graph depicting the dissolution profiles of 5-ASA tablets coated with 30% starch:70% Eudragit® S to various polymer weight gains in pH 6.8 buffer containing 50 U/ml amylase;
  • FIG. 10 is a graph depicting the dissolution profiles of prednisolone tablets coated with 70% Eudragit® S:30 starch having either 70 wt % or 27 wt % amylose in pH 7 buffer;
  • FIG. 11 is a graph depicting the dissolution profiles of prednisolone tablets as for FIG. 10 in pH 6.8 buffer;
  • FIG. 12 is a graph depicting the dissolution profiles of the prednisolone tablets as for FIG. 10 in pH 6.8 buffer containing 50 U/ml amylase;
  • FIG. 13 is a graph depicting the dissolution profile of prednisolone tablets coated with 70% Eudragit® L:30% starch to 8.3% TWG in pH 5.5 buffer;
  • FIG. 14 is a graph depicting the dissolution profile of prednisolone tablets as for FIG. 13 in pH 5.5 buffer containing 50 U/ml amylase;
  • FIG. 15 is a graph depicting the dissolution profile of prednisolone tablets coated with 70% HPMCAS-HG:30% starch in pH 6.5 buffer;
  • FIG. 16 is a graph depicting the dissolution profile of the prednisolone tablets as for FIG. 15 in pH 6.5 buffer containing 50 U/ml amylase;
  • FIG. 17 is a graph depicting the dissolution profile of the prednisolone tablets as for FIG. 15 in pH 6.8 buffer.
  • Prednisolone tablets (weight 200 mg, diameter 8 mm and standard bi-concave) were prepared according to the following formula:
  • Prednisolone was dry mixed with the excipients and then wet granulated. Granules of 500-710 ⁇ m size fraction were compressed using a single punch tabletting machine (Manesty, UK).
  • EurylonTM 7 starch was dispersed well in the butan-1-ol and water subsequently added with good agitation. The resulting dispersion was then heated to boiling, and cooled with stirring overnight. The % solids content of the cooled dispersion was calculated based on the final weight of the dispersion (allowing for evaporation during heating).
  • Eudragit® S solution was prepared by dissolution of Eudragit® S 100 polymer in 96% ethanol under high speed stirring. The final solution contained approximately 6% polymer solids.
  • the spray coating parameters were as follows:
  • Starch dispersion was prepared from Eurylon 7, a “high amylose” starch, and mixed with a solution of Eudragit® S in ethanol.
  • the composition and preparation method for the coating dispersions are as described above.
  • Various starch/Eudragit® S combinations were prepared containing 15%, 20%, 25%, 30% and 35% starch.
  • the mixed Eudragit®/starch coating dispersions were then film coated onto prednisolone tablets prepared according to the method described above. Tablets were coated to varying thicknesses, calculated as total weight gain on the polymer, to also determine the optimum coating thickness.
  • the coating mixture yielded good quality films up to a ratio of 30% starch.
  • Results are shown in FIGS. 1-7 .
  • these mixed film coated tablets were able to resist drug release in pH 1.2 HCl simulating the gastric media (see the left-hand side of the graphs of FIGS. 1-6 ).
  • FIGS. 1 to 5 Drug release profiles from the coated tablets in pH 7.0 buffer media are shown in FIGS. 1 to 5 . Based on an analysis of the dissolution profiles, tablets coated with a 30% starch/Eudragit® mixture to a film thickness equivalent to a TWG of 8.3% was judged to be optimal, and were further tested to assess the digestibility of the starch component of the film.
  • the tablets were dissolution tested in pH 6.8 buffer containing 50 U (units)/ml ⁇ -amylase derived from B. licheniformis (see FIG. 7 ).
  • a dissolution test was also carried out in pH 6.8 media with pancreatin to test whether the starch is digestible by pancreatic ⁇ -amylase (see FIG. 6 ).
  • Table 1 shows the site and time of disintegration of 30% starch and 70% Eudragit® S coated tablets in eight healthy male volunteers on three separate occasions.
  • Treatment 1 Treatment 2
  • Treatment 3 (Fasted) (Partial fasted) (Fed) Subject Site Time Site Time Site Time 1 ICJ 237 ICJ 244 AC 240 2 AC 200 ICJ 339 AC 316 3 AC 201 ICJ 350 AC 510 4 AC 292 HF 390 AC 415 5 TC 465 SF 678 AC 555 6
  • Subject did not — AC 523 AC 523 attend study day 7 AC 274 AC 244 SF 465 8 AC 614 Tablet did not — AC 455 empty from stomach
  • Tablets (weight 200 mg; diameter 8 mm; standard bi-concave) containing 5 wt % 5-aminosalicylic acid in place of wt % prednisolone were prepared and coated with a polymer mixture comprising 70% Eudragit® S:30% starch (EurylonTM 7) to 5%, 6%, 7% and 8.3% TWG in accordance with the procedure given in Example 1.
  • FIG. 8 indicates that for the 5-ASA tablet coated to 8.3% TWG there was no release of 5-ASA for about 9 hours with almost complete release after about 11 hours.
  • the 5-ASA tablets with each of the different TWGs were then tested in vitro for drug release in the presence of 50 U/ml ⁇ -amylase.
  • FIG. 9 indicates that drug release was much faster for all TWGs in the presence of ⁇ -amylase.
  • the 5-ASA tablet coated to 7% TWG gave a similar lag-time in pH 6.8 buffer (about 2 hours) as a 5 wt % prednisolone tablet coated to 8.3% TWG.
  • this result may be explained by 5-ASA exhibiting acidic properties as it dissolves in the near neutral buffer, thus reducing the pH at the tablet core/polymer boundary layer relative to the bulk medium and consequently retarding dissolution of the polymer coating.
  • Tablets (weight 200 mg; diameter 8 mm; standard bi-concave) containing 5 wt % prednisolone were prepared and coated with a polymer mixture comprising 70% Eudragit® S:30% starch to 8.3% TWG in accordance with the procedure given in Example 1.
  • the starch used was either a “high” amylose maize starch (EurylonTM 7; ⁇ 70 wt % amylose) or a “low” amylose starch (natural maize starch; ⁇ 27 wt % amylose; Sigma, Poole, UK).
  • the tablets were then tested in vitro for drug release in pH 7 buffer without amylase and then in pH 6.8 buffer, with and without 50 U/ml ⁇ -amylase.
  • FIGS. 10 and 11 indicate that drug release is quicker using “low” amylose starch.
  • FIG. 11 indicates that there is a lag-time of about 2.5 hours in small intestinal conditions for the “low” amylose starch tablets which was shorter than the lag time for the “high” amylose starch tablets. This result may be explained by noting that amylopectin is more water soluble than amylose. Thus, the greater the proportion of amylopectin, the quicker the coating dissolves in aqueous solution.
  • FIG. 12 indicates that drug release is substantially quicker in the presence of ⁇ -amylase.
  • the tablets having the coating containing “low” amylose starch have also been demonstrated (using the same procedure as for FIG. 6 ) to be indigestible to pancreatin for several hours, further substantiating the resistance of the “low” amylose system in the small intestine.
  • Such resistance is surprising as amylopectin is a substrate of pancreatic amylase (present in pancreatin) and, therefore, digestion of the coating and drug release would have been expected.
  • Tablets (weight 200 mg; diameter 8 mm; standard bi-concave) containing 5 wt % prednisolone were prepared and coated with a polymer mixture comprising 70% Eudragit® L:30% starch (EurylonTM 7) to 8.3% TWG in accordance with the procedure given in Example 1.
  • the tablets were then tested in vitro for drug release in pH 5.5 buffer, first without amylase and then with 50 U/ml ⁇ -amylase.
  • FIG. 13 indicates a lag time of just under 4 hours in small intestinal conditions. However, in the presence of ⁇ -amylase, the lag-time was about 3 hours ( FIG. 14 ). The results indicate that this coating system could be used for drug release in the proximal small intestine.
  • Tablets (weight 200 mg; diameter 8 mm; standard bi-concave) containing 5 wt % prednisolone were prepared and coated with a polymer mixture comprising 70% hydroxypropyl methylcellulose acetate succinate (“HPMCAS”):30% starch (Eurylon′ 7) to 8.3% TWG generally in accordance with the procedure given in Example 1.
  • HPMCAS 70% hydroxypropyl methylcellulose acetate succinate
  • the HPMCAS ShinEtsu, Japan
  • the HPMCAS-HG was dissolved in 90% ethanol and the aqueous dispersion of starch added to it.
  • the tablets were then tested in vitro for drug release in pH 6.5 buffer, first without amylase and then with 50 U/ml ⁇ -amylase. Further tablets were then tested in vitro for drug release in pH 6.8 buffer in the absence of ⁇ -amylase.
  • FIG. 15 indicates that the coating had a tendency to swell below the pH threshold of the HMPCAS-HG, allowing slow diffusion of the drug out of the formulation prior to dissolution of the coating and a burst of drug release.
  • the lag-time prior to the onset of diffusion in pH 6.5 buffer in the absence of ⁇ -amylase was about 2 hours which would be sufficient to retard release until the distal small intestine. Diffusion continued for approximately an additional 4.5 hours resulting in almost 40% of the drug diffusing out prior to the burst release.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
US11/735,248 2006-04-13 2007-04-13 Colonic drug delivery formulation Active 2029-10-30 US9023368B2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US14/676,225 US9993435B2 (en) 2006-04-13 2015-04-01 Colonic drug delivery formulation
US15/834,436 US10369112B2 (en) 2006-04-13 2017-12-07 Colonic drug delivery formulation
US16/354,683 US10668023B2 (en) 2006-04-13 2019-03-15 Colonic drug delivery formulation
US16/798,676 US10758491B2 (en) 2006-04-13 2020-02-24 Colonic drug delivery formulation
US15/929,260 US10857103B2 (en) 2006-04-13 2020-04-17 Colonic drug delivery formulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0607534.5 2006-04-13
GBGB0607534.5A GB0607534D0 (en) 2006-04-13 2006-04-13 Colonic drug delivery formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14/676,225 Continuation US9993435B2 (en) 2006-04-13 2015-04-01 Colonic drug delivery formulation

Publications (2)

Publication Number Publication Date
US20070243253A1 US20070243253A1 (en) 2007-10-18
US9023368B2 true US9023368B2 (en) 2015-05-05

Family

ID=36571851

Family Applications (6)

Application Number Title Priority Date Filing Date
US11/735,248 Active 2029-10-30 US9023368B2 (en) 2006-04-13 2007-04-13 Colonic drug delivery formulation
US14/676,225 Active 2027-05-02 US9993435B2 (en) 2006-04-13 2015-04-01 Colonic drug delivery formulation
US15/834,436 Active US10369112B2 (en) 2006-04-13 2017-12-07 Colonic drug delivery formulation
US16/354,683 Active US10668023B2 (en) 2006-04-13 2019-03-15 Colonic drug delivery formulation
US16/798,676 Active US10758491B2 (en) 2006-04-13 2020-02-24 Colonic drug delivery formulation
US15/929,260 Active US10857103B2 (en) 2006-04-13 2020-04-17 Colonic drug delivery formulation

Family Applications After (5)

Application Number Title Priority Date Filing Date
US14/676,225 Active 2027-05-02 US9993435B2 (en) 2006-04-13 2015-04-01 Colonic drug delivery formulation
US15/834,436 Active US10369112B2 (en) 2006-04-13 2017-12-07 Colonic drug delivery formulation
US16/354,683 Active US10668023B2 (en) 2006-04-13 2019-03-15 Colonic drug delivery formulation
US16/798,676 Active US10758491B2 (en) 2006-04-13 2020-02-24 Colonic drug delivery formulation
US15/929,260 Active US10857103B2 (en) 2006-04-13 2020-04-17 Colonic drug delivery formulation

Country Status (26)

Country Link
US (6) US9023368B2 (no)
EP (1) EP2018159B2 (no)
JP (5) JP5176017B2 (no)
KR (1) KR101360122B1 (no)
CN (1) CN101448488B (no)
AU (1) AU2007242648B8 (no)
BR (1) BRPI0710195B8 (no)
CA (2) CA2648658C (no)
CY (1) CY1113307T1 (no)
DK (1) DK2018159T4 (no)
ES (1) ES2390106T5 (no)
GB (1) GB0607534D0 (no)
HK (1) HK1128627A1 (no)
HR (1) HRP20120766T4 (no)
IL (2) IL194632A (no)
MX (1) MX2008013036A (no)
NO (1) NO344029B1 (no)
NZ (2) NZ778023A (no)
PL (1) PL2018159T5 (no)
PT (1) PT2018159E (no)
RS (1) RS52434B2 (no)
RU (2) RU2646825C2 (no)
SA (1) SA07280292B1 (no)
SI (1) SI2018159T2 (no)
WO (1) WO2007122374A2 (no)
ZA (1) ZA200808677B (no)

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170224719A1 (en) * 2016-02-09 2017-08-10 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10000528B2 (en) 2010-11-08 2018-06-19 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10183920B2 (en) 2014-10-24 2019-01-22 Elobix Ab Crystal modifications of elobixibat
US10441605B2 (en) * 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10744103B2 (en) 2015-09-01 2020-08-18 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US10881685B2 (en) 2017-08-09 2021-01-05 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US10975046B2 (en) 2018-06-20 2021-04-13 Albireo Ab Crystal modifications of odevixibat
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
WO2021188564A1 (en) 2020-03-16 2021-09-23 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
US11324708B1 (en) 2020-04-01 2022-05-10 UNION therapeutics A/S Niclosamide formulations for treating disease
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US12005086B2 (en) 2018-02-23 2024-06-11 Finch Therapeutics Holdings Llc Microbiome related immunotherapies

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
ES2425762T3 (es) 2008-10-27 2013-10-17 Roquette Freres Polímero insoluble en agua: revestimientos de película a base de derivados de almidón modificado para la liberación dirigida al colon
AU2009315898B2 (en) 2008-11-13 2015-07-23 Nogra Pharma Limited Antisense compositions and methods of making and using same
US9314444B2 (en) 2009-01-12 2016-04-19 Biokier, Inc. Composition and method for treatment of NASH
US9006288B2 (en) 2009-01-12 2015-04-14 Biokier, Inc. Composition and method for treatment of diabetes
WO2013030726A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Programmed drug delivery
RS56839B1 (sr) * 2012-04-30 2018-04-30 Tillotts Pharma Ag Formulacija leka sa odloženim otpuštanjem
RU2650636C2 (ru) 2012-05-03 2018-04-16 Янссен Сайенсиз Айрлэнд Юси Составы на основе полиинозиновой-полицитидиловой кислоты (poly(i:с)) для лечения инфекций верхних дыхательных путей
US10799515B2 (en) * 2013-10-29 2020-10-13 Tillotts Pharma Ag Delayed release drug formulation
SI2946774T1 (sl) * 2014-05-19 2020-07-31 Tillotts Pharma Ag Obložene kapsule s prirejenim sproščanjem
CN117599029A (zh) 2016-03-17 2024-02-27 硫创治疗公司 用于控制释放半胱胺和系统治疗半胱胺敏感性病症的组合物
EP3257501A1 (en) 2016-06-14 2017-12-20 Tillotts Pharma AG Multiple unit dosage form comprising a core with individual core units covered by a mucoadhesive material, and an enteric core coating
CN107540761B (zh) * 2016-06-27 2020-08-11 中国科学院微生物研究所 一种耐酸型普鲁兰多糖衍生物及其制备方法
CN106380636B (zh) * 2016-08-30 2019-05-14 华南理工大学 一种壳聚糖接枝的抗消化淀粉载体材料及其制备方法和应用
EP3409688A1 (en) 2017-05-31 2018-12-05 Tillotts Pharma Ag Topical treatment of inflammatory bowel disease using anti-tnf-alpha antibodies and fragments thereof
EP3459527B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Method for preparing a solid dosage form comprising antibodies by wet granulation, extrusion and spheronization
EP3459528B1 (en) 2017-09-20 2022-11-23 Tillotts Pharma Ag Preparation of solid dosage forms comprising antibodies by solution/suspension layering
EP3684418A4 (en) 2017-09-20 2021-06-16 Thiogenesis Therapeutics, Inc. TREATMENT METHODS FOR CYSTEAMINE SENSITIVE CONDITIONS
EP3459529A1 (en) 2017-09-20 2019-03-27 Tillotts Pharma Ag Preparation of sustained release solid dosage forms comprising antibodies by spray drying
MX2021002686A (es) 2018-09-06 2021-08-11 Fachhochschule Nordwestschweiz Formulacion controlada de liberacion de farmacos.
EP3662901A1 (en) * 2018-12-07 2020-06-10 Tillotts Pharma AG Delayed release drug formulation comprising an outerlayer with an enzymaticyaaly degradable polymer, its composition and its method of manufacturing
EP3662902B1 (en) * 2018-12-07 2024-07-31 Tillotts Pharma AG Colonic drug delivery formulation
EP3662895A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG A process for manufacturing reducing sugar-free 5-asa tablet cores
EP3662900A1 (en) 2018-12-07 2020-06-10 Tillotts Pharma AG Colonic drug delivery formulation
WO2020114616A1 (en) 2018-12-07 2020-06-11 Tillotts Pharma Ag Topical treatment of immune checkpoint inhibitor induced diarrhoea, colitis or enterocolitis using antibodies and fragments thereof
GB201905940D0 (en) 2019-04-29 2019-06-12 Intract Pharma Ltd 5-aminolevulinic acid for the local treatment of inflammatory bowel disease
EP3968969A1 (en) 2019-05-15 2022-03-23 Evonik Operations GmbH Process for preparing filled hard-shell capsules with (meth)acrylate copolymer based coatings with a capsule-filling machine
GB201906917D0 (en) 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
GB201906906D0 (en) 2019-05-16 2019-07-03 Intract Pharma Ltd Novel compositions
AU2020316330A1 (en) 2019-07-19 2022-01-06 Finch Therapeutics Holdings Llc. Methods and products for treatment of gastrointestinal disorders
KR102104507B1 (ko) * 2019-08-23 2020-04-24 브릿지바이오테라퓨틱스(주) 팔미토일-l-프롤릴-l-프롤릴-글리실-l-타이로신 나트륨을 포함하는 약제학적 제제 및 이의 제조방법
JP2022547330A (ja) 2019-09-13 2022-11-11 フィンチ セラピューティクス ホールディングス エルエルシー 自閉症スペクトラム障害を治療するための組成物および方法
US20240226187A9 (en) 2019-10-18 2024-07-11 Finch Therapeutics Holdings Llc Compositions and Methods for Delivering a Bacterial Metabolite to a Subject
WO2021097288A1 (en) 2019-11-15 2021-05-20 Finch Therapeutics Holdings Llc Compositions and methods for treating neurodegenerative diseases
WO2021142347A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for non-alcoholic steatohepatitis (nash)
WO2021142358A1 (en) 2020-01-10 2021-07-15 Finch Therapeutics Holdings Llc Compositions and methods for treating hepatic encephalopathy (he)
TW202140049A (zh) 2020-01-10 2021-11-01 美商芬奇治療控股有限責任公司 用於治療ｂ型肝炎（ｈｂｖ）及ｄ型肝炎（ｈｄｖ）之組合物及方法
US20230201265A1 (en) 2020-03-31 2023-06-29 Finch Therapeutics Holdings Llc Compositions comprising non-viable fecal microbiota and methods of use thereof
GB202017863D0 (en) 2020-11-12 2020-12-30 Intract Pharma Ltd Novel compositions
US20240263251A1 (en) 2021-02-19 2024-08-08 Finch Therapeutics Holdings Llc Compositions and methods for providing secondary bile acids to a subject
EP4426354A2 (en) * 2021-11-03 2024-09-11 The University of Chicago Prodrug copolymers and polymeric micelles thereof for the delivery of short-chain fatty acids, the promotion of gut health, and the treatment of conditions
WO2023102491A1 (en) * 2021-12-01 2023-06-08 Invea Therapeutics, Inc. Methods for treating gastrointestinal inflammatory disease
US20240165060A1 (en) * 2021-12-17 2024-05-23 Biokier, Inc. Method and composition for lowering total systemic cholestrol, ldl cholesterol, and non-hdl cholesterol
GB202201708D0 (en) 2022-02-10 2022-03-30 Intract Pharma Ltd Compositions for oral delivery of biotherapeutics

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343993A1 (en) 1988-05-26 1989-11-29 Btg International Limited Delayed release formulations
WO1991007949A1 (en) 1989-11-24 1991-06-13 British Technology Group Ltd. Delayed release formulations
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
WO1999021536A1 (en) 1997-10-23 1999-05-06 Btg International Limited Controlled release formulations
WO1999025325A1 (en) 1997-11-14 1999-05-27 Btg International Limited Low temperature coatings
WO1999052512A1 (en) * 1998-03-27 1999-10-21 Valtion Teknillinen Tutkimuskeskus Coated starch capsules and a process for producing them
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
WO2001076562A1 (en) 2000-04-03 2001-10-18 Novasso Oy A peroral pharmaceutical formulation for controlled release of a drug
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
EP1203590A1 (en) 1999-08-09 2002-05-08 Dainippon Pharmaceutical Co., Ltd. Solid preparations containing chitosan powder and process for producing the same
WO2003068196A1 (en) 2002-02-13 2003-08-21 Alizyme Therapeutics Limited Colonic release composition
WO2004052339A1 (en) 2002-12-09 2004-06-24 Salvona Llc Ph triggered targeted controlled release systems
WO2007013794A1 (en) 2005-07-29 2007-02-01 Stichting Groningen Centre For Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof
US20070276047A1 (en) * 2005-06-27 2007-11-29 Biovail Laboratories International S.R.L. Modified release formulations of a bupropion salt

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825384B (en) * 1981-07-31 1983-05-25 Tillott J B Ltd Orally administrable pharmaceutical compositions
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
ATE185267T1 (de) * 1990-05-04 1999-10-15 Perio Prod Ltd System zur arzneistoffabgabe im colon
DK0661045T3 (da) * 1992-09-18 2002-10-28 Yamanouchi Pharma Co Ltd Hydrogelpræparat med forsinket frigivelse
DE69528583T2 (de) * 1994-04-22 2003-07-10 Yamanouchi Pharmaceutical Co., Ltd. Kolon-spezifisches arzneistofffreisetzungssystem
GB9412394D0 (en) * 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US6248362B1 (en) * 1997-03-26 2001-06-19 Meiji Seika Kaisha, Ltd. Large intestinal delivery composite
CN1475209A (zh) * 1997-07-01 2004-02-18 �Ʒ� 舍曲林的缓释剂型
CN1201736C (zh) * 2002-07-19 2005-05-18 安徽省药物研究所 甲硝唑结肠定位缓释制剂
EP1670442A4 (en) * 2003-09-19 2011-09-14 Penwest Pharmaceuticals Co DOSAGE FORMS WITH DELAYED RELEASE
CZ2004964A3 (cs) * 2004-09-14 2006-03-15 Pliva-Lachema A. S. Perorální farmaceutická kompozice pro cílený transport komplexu platiny do kolorektální oblasti, zpusob její prípravy a tato kompozice pro pouzití jako lécivo
GB0607534D0 (en) * 2006-04-13 2006-05-24 Univ London Pharmacy Colonic drug delivery formulation
JP6148210B2 (ja) * 2014-06-17 2017-06-14 東京エレクトロン株式会社 現像方法及びコンピュータ読み取り可能な記録媒体

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0343993A1 (en) 1988-05-26 1989-11-29 Btg International Limited Delayed release formulations
WO1991007949A1 (en) 1989-11-24 1991-06-13 British Technology Group Ltd. Delayed release formulations
US5294448A (en) * 1989-11-24 1994-03-15 British Technology Group Limited Delayed release formulations
US5422121A (en) * 1990-11-14 1995-06-06 Rohm Gmbh Oral dosage unit form
WO1999021536A1 (en) 1997-10-23 1999-05-06 Btg International Limited Controlled release formulations
WO1999025325A1 (en) 1997-11-14 1999-05-27 Btg International Limited Low temperature coatings
US6251430B1 (en) 1998-02-04 2001-06-26 Guohua Zhang Water insoluble polymer based sustained release formulation
WO1999052512A1 (en) * 1998-03-27 1999-10-21 Valtion Teknillinen Tutkimuskeskus Coated starch capsules and a process for producing them
EP1203590A1 (en) 1999-08-09 2002-05-08 Dainippon Pharmaceutical Co., Ltd. Solid preparations containing chitosan powder and process for producing the same
WO2001076562A1 (en) 2000-04-03 2001-10-18 Novasso Oy A peroral pharmaceutical formulation for controlled release of a drug
GB2367002A (en) 2000-09-25 2002-03-27 British Sugar Plc Coating composition
WO2003068196A1 (en) 2002-02-13 2003-08-21 Alizyme Therapeutics Limited Colonic release composition
WO2004052339A1 (en) 2002-12-09 2004-06-24 Salvona Llc Ph triggered targeted controlled release systems
US20070276047A1 (en) * 2005-06-27 2007-11-29 Biovail Laboratories International S.R.L. Modified release formulations of a bupropion salt
WO2007013794A1 (en) 2005-07-29 2007-02-01 Stichting Groningen Centre For Drug Research Ph-controlled pulsatile delivery system, methods for preparation and use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A. Akhgari, et al., "Permeability and Swelling Studies on Free Films Containing Insulin in Combination With Different Polymethacrylates Aimed for Colonic Drug Delivery", European Journal of Pharmaceutical Sciences, 28, 2006, pp. 307-314.
A. W. Basit, et al., "The Use of Formulation Technology to Assess Regional Gastrointestinal Drug Absorption in Humans", European Journal of Pharmaceutical Sciences, 21, 2004, pp. 179-189.
K. Krogars, et al., "Tablet Film-Coating With Amylose-Rich Maize Starch", European Journal of Pharmaceutical Sciences, 17, 2002, pp. 23-30.
S. Milojevic, et al., "Amylose as a Coating for Drug Delivery to the Colon: Preparation and In Vitro Evaluation Using 5-Aminosalicylic Acid Pellets", Journal of Controlled Release, 38, 1996, pp. 75-84.

Cited By (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10000528B2 (en) 2010-11-08 2018-06-19 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10011633B2 (en) 2010-11-08 2018-07-03 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10093697B2 (en) 2010-11-08 2018-10-09 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10221212B2 (en) 2010-11-08 2019-03-05 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US11732006B2 (en) 2010-11-08 2023-08-22 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10487111B2 (en) 2010-11-08 2019-11-26 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US11261212B2 (en) 2010-11-08 2022-03-01 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10981952B2 (en) 2010-11-08 2021-04-20 Albireo Ab IBAT inhibitors for the treatment of liver diseases
US10709755B2 (en) 2014-06-25 2020-07-14 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US11844822B2 (en) 2014-06-25 2023-12-19 Elobix Ab Solid formulation and method for preventing or reducing coloration thereof
US10183920B2 (en) 2014-10-24 2019-01-22 Elobix Ab Crystal modifications of elobixibat
US10519120B2 (en) 2014-10-24 2019-12-31 Elobix Ab Crystal modifications of elobixibat
US10799468B2 (en) 2015-09-01 2020-10-13 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US10849867B2 (en) 2015-09-01 2020-12-01 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory response
US11793777B2 (en) 2015-09-01 2023-10-24 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory response
US10744103B2 (en) 2015-09-01 2020-08-18 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory responses
US10912746B2 (en) 2015-09-01 2021-02-09 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory response
US10905666B2 (en) 2015-09-01 2021-02-02 First Wave Bio, Inc. Methods and compositions for treating conditions associated with an abnormal inflammatory response
US10799527B2 (en) 2016-02-09 2020-10-13 Albireo Ab Oral cholestyramine formulation and use thereof
US20170224719A1 (en) * 2016-02-09 2017-08-10 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10441604B2 (en) * 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10864228B2 (en) 2016-02-09 2020-12-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10610543B2 (en) 2016-02-09 2020-04-07 Albireo Ab Cholestyramine pellets and methods for preparation thereof
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10758563B2 (en) 2016-02-09 2020-09-01 Albireo Ab Oral cholestyramine formulation and use thereof
US10493096B2 (en) 2016-02-09 2019-12-03 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) * 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
US10588864B2 (en) 2016-03-11 2020-03-17 Gateway Pharmaceuticals LLC Pharmaceutical compositions for colon-specific delivery
US10881685B2 (en) 2017-08-09 2021-01-05 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
US12005086B2 (en) 2018-02-23 2024-06-11 Finch Therapeutics Holdings Llc Microbiome related immunotherapies
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11802115B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US10975046B2 (en) 2018-06-20 2021-04-13 Albireo Ab Crystal modifications of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
WO2021142238A1 (en) 2020-01-10 2021-07-15 First Wave Bio, Inc. Deuterated niclosamide
US11564896B2 (en) 2020-03-16 2023-01-31 First Wave Bio, Inc. Methods of treatment
WO2021188564A1 (en) 2020-03-16 2021-09-23 First Wave Bio, Inc. Methods of treating covid-19 with a niclosamide compound
US11744812B2 (en) 2020-03-16 2023-09-05 First Wave Bio, Inc. Methods of treatment
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
US11324708B1 (en) 2020-04-01 2022-05-10 UNION therapeutics A/S Niclosamide formulations for treating disease

Also Published As

Publication number Publication date
JP2017095507A (ja) 2017-06-01
KR101360122B1 (ko) 2014-02-06
PL2018159T3 (pl) 2012-11-30
US10668023B2 (en) 2020-06-02
HK1128627A1 (en) 2009-11-06
JP5176017B2 (ja) 2013-04-03
EP2018159B1 (en) 2012-06-27
EP2018159A2 (en) 2009-01-28
MX2008013036A (es) 2009-01-20
NO344029B1 (no) 2019-08-19
US9993435B2 (en) 2018-06-12
ES2390106T3 (es) 2012-11-06
BRPI0710195B8 (pt) 2021-05-25
WO2007122374A8 (en) 2009-03-19
DK2018159T3 (da) 2012-10-01
PT2018159E (pt) 2012-10-03
BRPI0710195A2 (pt) 2011-08-09
NO20084292L (no) 2009-01-09
US10758491B2 (en) 2020-09-01
AU2007242648B8 (en) 2012-08-30
IL250674B (en) 2020-05-31
ZA200808677B (en) 2010-02-24
HRP20120766T4 (hr) 2020-07-10
CY1113307T1 (el) 2016-04-13
JP2015134806A (ja) 2015-07-27
NZ778023A (en) 2023-01-27
SA07280292B1 (ar) 2012-01-04
RU2008144700A (ru) 2010-05-20
SI2018159T2 (sl) 2020-08-31
JP2013047250A (ja) 2013-03-07
US20200237676A1 (en) 2020-07-30
CA2648658C (en) 2013-11-12
SI2018159T1 (sl) 2012-11-30
US10369112B2 (en) 2019-08-06
JP2009533408A (ja) 2009-09-17
DK2018159T4 (da) 2020-05-18
US20180098944A1 (en) 2018-04-12
CA2648658A1 (en) 2007-11-01
HRP20120766T1 (en) 2012-10-31
CA2825758A1 (en) 2007-11-01
AU2007242648B2 (en) 2012-08-09
IL250674A0 (en) 2017-04-30
PL2018159T5 (pl) 2020-10-05
NZ767015A (en) 2022-02-25
GB0607534D0 (en) 2006-05-24
US20150202162A1 (en) 2015-07-23
RU2012153207A (ru) 2014-06-20
AU2007242648A1 (en) 2007-11-01
IL194632A (en) 2017-03-30
NZ572760A (en) 2012-11-30
EP2018159B2 (en) 2020-04-01
WO2007122374A3 (en) 2007-12-21
US10857103B2 (en) 2020-12-08
JP6273387B2 (ja) 2018-01-31
US20200206142A1 (en) 2020-07-02
WO2007122374A2 (en) 2007-11-01
CN101448488B (zh) 2012-11-14
BRPI0710195B1 (pt) 2020-08-04
RS52434B2 (sr) 2020-09-30
US20190254980A1 (en) 2019-08-22
RU2646825C2 (ru) 2018-03-07
JP2018076362A (ja) 2018-05-17
ES2390106T5 (es) 2020-11-20
NZ785519A (en) 2023-08-25
KR20090032029A (ko) 2009-03-31
US20070243253A1 (en) 2007-10-18
RU2478372C2 (ru) 2013-04-10
RS52434B (en) 2013-02-28
CN101448488A (zh) 2009-06-03

Similar Documents

Publication Publication Date Title
US10857103B2 (en) Colonic drug delivery formulation
EP3187171B1 (en) A delayed release drug formulation
AU2012247013B2 (en) Colonic drug delivery formulation
TWI422398B (zh) 結腸給藥配方
NZ748404B2 (en) Colonic drug delivery formulation
NZ748404A (en) Colonic drug delivery formulation
NZ785519B2 (en) Colonic drug delivery formulation
NZ767015B2 (en) Colonic drug delivery formulation

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHOOL OF PHARMACY, UNIVERSITY OF LONDON, UNITED K

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BASIT, ABDUL WASEH;IBEKWE, VALENTINE CHIDI;REEL/FRAME:019494/0325

Effective date: 20070612

AS Assignment

Owner name: UNIVERSITY COLLEGE LONDON, UNITED KINGDOM

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:THE SCHOOL OF PHARMACY, UNIVERSITY OF LONDON;REEL/FRAME:029151/0326

Effective date: 20120124

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1551); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 4

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 8TH YEAR, LARGE ENTITY (ORIGINAL EVENT CODE: M1552); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

Year of fee payment: 8